Share chart Quince Therapeutics, Inc.
Extended chart
Simple chart
About
Quince Therapeutics, Inc., биофармацевтическая компания, специализируется на разработке прецизионных терапевтических средств для изнурительных и редких заболеваний. Компания открыла обширную платформу лекарственных средств, нацеленных на кости, для точной доставки малых молекул, пептидов или больших молекул непосредственно в место перелома кости и заболевания. Его ведущим соединением является NOV004, анаболический пептид, разработанный для точного нацеливания и концентрации в месте перелома кости. Ранее компания называлась Cortexyme, Inc.
More details| Цена ао | 1.62 |
|---|---|
| Сайт | https://www.quincetx.com |
| ISIN | US22053A1079 |
| EBITDA | -0.037 |
| EV/EBITDA | -23.58 |
| P/BV | 7.99 |
| Число акций ао | 0.03724 млрд |
| Валюта | usd |
| IPO date | 2019-05-09 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +37.29% (1.18) |
|---|---|
| Change price per week: | +90.59% (0.85) |
| Change price per month: | +87.22% (0.8653) |
| Change price per 3 month: | +107.69% (0.78) |
| Change price per half year: | +52.83% (1.06) |
| Change price per year: | +67.01% (0.97) |
| Change price per 3 year: | -97.43% (63.05) |
| Change price per 5 year: | -94.15% (27.69) |
| Change price per year to date: | +80% (0.9) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Tang Capital Management, LLC | 3220000 | 7.45 |
| Vanguard Group Inc | 971801 | 2.25 |
| EPIQ Capital Group, LLC | 870133 | 2.01 |
| Renaissance Technologies, LLC | 458680 | 1.06 |
| Blackrock Inc. | 335604 | 0.78 |
| Geode Capital Management, LLC | 261738 | 0.61 |
| Alphabet Inc. | 189122 | 0.44 |
| Bank of America Corporation | 170031 | 0.39 |
| Bridgeway Capital Management, Inc. | 138495 | 0.32 |
| JANE STREET GROUP, LLC | 119741 | 0.28 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00829 | 36.318555985322 | 1.54048 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director | 681.36k | 1970 (54 years) |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer | 504.34k | 1986 (38 years) |
| Ms. Stacy Roughan | Vice President of Corporate Communications & Investor Relations | N/A | |
| Ms. Mary Ellen Sillivos | Vice President of Human Resources | N/A | |
| Dr. Stewart A. Low Ph.D. | Head of Discovery | N/A | |
| Dr. Charles S. Ryan J.D., Ph.D. | President | N/A | 1964 (60 years) |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer | N/A | |
| Mr. Giovanni Mambrini M.Sc. | Chief Technology Officer | ||
| Mr. Thomas Sabia M.B.A. | Chief Commercial Officer | ||
| Ms. Pamela M. Williamson FRAPS, M.B.A., RAC | Head of Regulatory Affairs |
Address: United States, South San Francisco. CA, 601 Gateway Blvd - open in Google maps, open in Yandex maps
Website: https://www.quincetx.com
Website: https://www.quincetx.com
